Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Ying-Ying HanLin ZhouYun-Lian HuXiang-Wu DingHui LongFei LiuMing XuZhen-Yu ZhangShuang-Ling LiQiu-Yan WangCheng-Xia SuYan ChenJie ChenYa LinPei Yuan LiPublished in: Journal of gastroenterology (2023)
The 10-day VA dual therapy was non-inferior to the 14-day RA dual therapy for H. pylori treatment-naive patients, which should be given priority in the first-line treatment. The application of vonoprazan reduced treatment course and antibiotic use. Patients' adherence was crucial for the success of eradication.
Keyphrases
- helicobacter pylori infection
- newly diagnosed
- helicobacter pylori
- randomized controlled trial
- prognostic factors
- stem cells
- rheumatoid arthritis
- hiv infected
- type diabetes
- metabolic syndrome
- mesenchymal stem cells
- skeletal muscle
- insulin resistance
- weight loss
- idiopathic pulmonary fibrosis
- phase ii
- placebo controlled
- phase iii
- clinical evaluation